AzurRx (AZRX) Corporate Media Kit

36 Summary of Key Combination Therapy Trial Interim Findings Primary Efficacy Endpoint • CFA > 80% for all patients, across all visits Secondary Efficacy Endpoints • Stool Weight decreased • The number of Stools/Day decreased • Steatorrhea improved • Body Weight increased Safety • Safe - no Serious Adverse Events